Peter Vuylsteke

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Fátima Cardoso, Laura J. van’t Veer, Jan Bogaerts et al. · New England Journal of Medicine · 2016 · 2K citations · Full text

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Amit M. Oza, David Cibula, Ana Oaknin Benzaquen et al. · The Lancet Oncology · 2014 · 540 citations

Medicine, Randomised Phase 2, Gynecology +6

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

José Baselga, Seock‐Ah Im, Hiroji Iwata et al. · The Lancet Oncology · 2017 · 532 citations · Full text

Advanced Breast Cancer, Breast Oncology, Oncology +13

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

Evandro de Azambuja, Andrew Holmes, Martine Piccart et al. · The Lancet Oncology · 2014 · 452 citations

Survival Outcomes, Breast Oncology, Medicine +7

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Martine Piccart, Laura van ‘t Veer, Coralie Poncet et al. · The Lancet Oncology · 2021 · 336 citations · Full text

Breast Oncology, Early Breast Cancer, Medicine +11